BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · Real-Time Price · USD

4.090

-0.060 (-1.45%)

At close: Sep 22, 2026, 4:00 PM EDT

4.150

+0.060 (1.47%)

After-hours: Sep 22, 2026, 7:30 PM EDT

BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Selling, General & Admin	6.71	6.39	6.57	8.51	7.58	4.96
Research & Development	25.31	20.81	26.76	14.76	7.71	2.02
Operating Expenses	32.03	27.2	33.33	23.27	15.29	6.98
Operating Income	-32.03	-27.2	-33.33	-23.27	-15.29	-6.98
Interest Expense	-0.03	-0.04	-	-	-0	-0.08
Interest & Investment Income	0.5	0.12	0.29	0.89	0.14	0
Earnings From Equity Investments	-0.22	-0.22	-0.11	-	-	-
Currency Exchange Gain (Loss)	-0.05	-0.02	-0.03	-0.04	-0.03	-2.18
Other Non Operating Income (Expenses)	0.8	0.76	28.24	2.12	-11.65	-4.45
EBT Excluding Unusual Items	-31.03	-26.61	-4.93	-20.3	-26.84	-13.67
Gain (Loss) on Sale of Investments	0.06	0.06	-	-	-	-
Other Unusual Items	-	-	-	-	-	-0.14
Pretax Income	-30.98	-26.56	-4.93	-20.3	-26.84	-13.82
Earnings From Continuing Operations	-30.98	-26.56	-4.93	-20.3	-26.84	-13.82
Minority Interest in Earnings	0.3	0.24	0.14	-	-	-
Net Income	-30.68	-26.31	-4.79	-20.3	-26.84	-13.82
Net Income to Common	-30.68	-26.31	-4.79	-20.3	-26.84	-13.82
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	3	0	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0	0
Shares Change	1260.31%	285.70%	5.35%	0.81%	242.82%	-
EPS (Basic)	-9.66	-62.19	-43.68	-194.97	-259.83	-458.54
EPS (Diluted)	-9.66	-62.19	-43.68	-194.97	-259.83	-458.54
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Free Cash Flow	-30.95	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-9.74	-66.58	-224.09	-228.03	-120.86	-257.22
EBITDA	-31.92	-27.1	-33.25	-23.26	-15.27	-6.96
D&A For EBITDA	0.11	0.11	0.08	0.02	0.02	0.02
EBIT	-32.03	-27.2	-33.33	-23.27	-15.29	-6.98

SEC Filings: 10-K · 10-Q